Europäisches Patentamt | Eur pean Patent Office | Office eur péen des brevets

# Bescheinigung | Certificate | Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr. | Patent application No. | Demande de brevet n°**

02026835.5

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

**R C van Dijk**

Anmeldung Nr:
Application no.: 02026835.5
Demande no:

Anmeldetag:
Date of filing: 29.11.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Aventis Behring Gesellschaft mit
beschränkter Haftung
Postfach 1230
35002 Marburg
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Modified cDNA factor VIII and its derivates

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s) revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12N15/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

**Aventis Behring GmbH**
**ANR 8177007**

**2002/M018 (A66)**
**Dr. Pfe/ns**

# Modified cDNA Factor VIII and its Derivatives

The present invention relates to modified DNA sequences coding for biologically active recombinant human factor VIII and its derivatives with improved stability, recombinant expression vectors containing such DNA sequences, host cells transformed with such recombinant expression vectors, and processes for the manufacture of the recombinant human factor VIII and its derivatives. The invention also covers a transfer vector for use in human gene therapy which comprises such modified DNA sequences.

Classic hemophilia or hemophilia A is the most common of the inherited bleeding disorders. It results from a chromosome X-linked deficiency of blood coagulation factor VIII, and affects almost exclusively males with an incidence of between one and two individuals per 10.000. The X-chromosome defect is transmitted by female carriers who are not themselves hemophiliacs. The clinical manifestation of hemophilia A is an abnormal bleeding tendency and before treatment with factor VIII concentrates was introduced the mean life span for a person with severe hemophilia was less than 20 years. The use of concentrates of factor VIII from plasma has considerably improved the situation for the hemophilia patients. The mean life span has increased extensively, giving most of them the possibility to live a more or less normal life. However, there have been certain problems with the plasma derived concentrates and their use, the most serious of which have been the transmission of viruses. So far, viruses causing AIDS, hepatitis B, and non A

non B hepatitis have hit the population seriously. Although different virus inactivation methods and new highly purified factor VIII concentrates have recently been developed an inadvertant contamination can not be excluded. Also, the factor VIII concentrates are fairly expensive because of the limited supply of human plasma raw material.

A factor VIII product derived from recombinant material is likely to solve a large extent of the problems associated with the use of plasma derived factor VIII concentrates for treatment for hemophilia A. However, the development of a recombinant factor VIII has met some difficulties, for instance the problem of achieving production levels in sufficiently high yields, in particular regarding the full-length molecule.

In fresh plasma prepared in the presence of protease inhibitors, factor VIII has been shown to have a molecular weight of 280 kDa and to be composed of two polypeptide chains of 200 kDa and 80 kDa, respectively (Andersson, L.-O., et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2979-2983). These chains are held together by metal ion bridges. More or less proteolytically degraded forms of the factor VIII molecule can be found as active fragments in factor VIII material purified from commercial concentrates (Andersson, L.-O., et al. ibid.; Andersson, L.-O., et al. (1985) EP 0 197 901). The fragmented form of factor VIII having molecular weights from 260 kDa down to 170 kDa, consists of one heavy chain with a molecular weight ranging from 180 kDa down to 90 kDa, where all variants have identical amino termini, in combination with one 80 kDa light chain. The amino-terminal region of the heavy chain is identical to that of the single chain factor VIII polypeptide that can be deduced from the nucleotide sequence data of the factor VIII cDNA (Wood, W.I., et al. (1984) Nature 312, 330-336; Vehar, G.A., et al. (1984) Nature 312, 337-342).

The smallest active form of factor VIII with a molecular weight of 170 kDa, consisting of one 90 kDa and one 80 kDa chain, can be activated with thrombin to

the same extent as the higher molecular weight forms, and thus represents an unactivated form. It has also been shown to have full biological activity in vivo as tested in hemophilia dogs (Brinkhous, K.M., et al. (1985) Proc. Natl. Acad. Sci. USA 82, 8752-8756). Thus, the haemostatic effectiveness of the 170 kDa form is the same as for the high molecular weight forms of factor VIII.

The fact that the middle heavily glycosylated region of the factor VIII polypeptide chain residing between amino acids Arg-740 and Glu-1649 does not seem to be necessary for full biological activity has prompted several researchers to attempt to produce derivatives of recombinant factor VIII lacking this region. This has been achieved by deleting a portion of the cDNA encoding the middle heavily glycosylated region of factor VIII either entirely or partially.

For example, J.J. Toole, et al, reported the construction and expression of factor VIII lacking amino acids 982 through 1562, and 760 through 1639 respectively (Proc. Natl. Acad. Sci. USA (1986) 83, 5939-5942). D.L. Eaton, et al. reported the construction and expression of factor VIII lacking amino acids 797 through 1562 (Biochemistry (1986) 25, 8343-8347). R.J. Kaufman described the expression of factor VIII lacking amino acids 741 through 1646 (PCT application No. WO 87/04187). N. Sarver, et al. reported the construction and expression of factor VIII lacking amino acids 747 through 1560 (DNA (1987) 6, 553-564). M. Pasek reported the construction and expression of factor VIII lacking amino acids 745 through 1562, and amino acids 741 through 1648, respectively (PCT application No. WO 88/00831). K.-D. Langner reported the construction and expression of factor VIII lacking amino acids 816 through 1598, and amino acids 741 through 1689, respectively (Behring Inst. Mitt., (1988) No. 82, 16-25, EP 0 295 597). P. Meulien, et al., reported the construction and expression of factor VIII lacking amino acids 868 through 1562, and amino acids 771 through 1666, respectively (Protein Engineering (1988) 2(4), 301-306, EP 0 303 540). When expressing these deleted forms of factor VIII cDNA in mammalian cells the production level is typically 10 times higher as compared to full-length factor VIII.

FVIII is secreted into plasma as a heterodimer of a heavy chain (domains A1-A2-B) and a light chain (A3-C1-C2) associated through a noncovalent divalent metal ion linkage between the A1- and A3 domains. In plasma, FVIII is stabilized by binding to von Willebrand factor.

Upon proteolytic activation by thrombin, FVIII is activated to a heterotrimer of 2 heavy chain fragments (A1, a 50 kDa fragment, and A2 a 43 kDa fragment) and the light chain (A3-C1-C2, a 73 kDa fragment). The active form of FVIII (FVIIIa) thus consists of an A1-subunit associated through the divalent metal ion linkage to a thrombin-cleaved A3-C1-C2 light chain and a free A2 subunit associated with the A1 domain . The dissociation of that free A2 subunit from the heterotrimer is thought to be the rate limiting step in FVIIIa inactivation after thrombin activation (Fay, P.J. et al, J. Biol. Chem. 266: 8957 (1991), Fay PJ & Smudzin TM, J. Biol. Chem. 267: 13246-50 (1992)). The half life of FVIIIa in plasma is only 2.1 minutes (Saenko et al., Vox Sang. 83: 89-96 (2002)). To enhance the half life of FVIIIa would result into a longer acting FVIIIa which would also translate into less frequent injections of such a FVIII preparation. The inactivation of FVIIIa through activated Protein C (APC) by cleavage at Arg336 and Arg562 is thought not to be the rate limiting step. Attempts have been made to create a FVIIIa which is inactivation resistant by covalently attaching the A2 domain to the A3 domain and by mutating the APC cleavage sites (Pipe and Kaufman, PNAS, 94:11851-11856). However such a FVIIIa could have a thrombogenic potential as it is almost completely inactivation resistant. It is therefore the purpose of this invention to create a FVIIIa in which the A2 domain is stabilized without completely blocking inactivation.

FVIII is administered i.v. to haemophilia patients who are on prophylactic treatment about 3 times per week due to the plasma half life of FVIII of about 12 hours. It would thus be highly desirable to create a FVIII with enhanced plasma half life which could lead to a FVIII preparation which has to be administered less

frequently. The present invention offers a solution to this problem by a modified FVIII molecule with an increased association of A2 to the A1/A3-C1-C2.

The nature of these modifications was identified by comparing the sequence of porcine FVIII to that of human FVIII as it is known that the dissociation of human A2 domain is threefold enhanced versus that of porcine A2 (Lollar et al., J Biol. Chem., 267:23652-23657 (1992)). The sequence comparison (Fig. 1) revealed several differences. A subset of these differences consists of differently charged amino acids. Mutants of human FVIII were constructed according to the following guidelines. When the human sequence contained a neutral amino acid whereas the porcine sequence contained a charged amino acid then a charged amino acid with the same charge as found in the porcine sequence was introduced into the human sequence. When the human sequence contained a charged amino acid whereas the porcine FVIII contained a neutral amino acid then a neutral amino acid or an amino acid of the opposite charge was introduced, e.g. if the human FVIII contained an acidic amino acid at a position where the porcine FVIII contained a neutral amino acid, also a basic amino acid was introduced. When the human sequence contained a charged sequence whereas the porcine FVIII contained a charged amino acid then an amino acid with the same charge as found in the porcine amino acid was introduced into the human sequence. Examples for such mutations which lead to an improved FVIII with a plasma half life of its activated form of more than three minutes, preferably of more than 10 minutes even more preferably more than 30 minutes, are listed in figure 2.

Other mutations for an improved FVIII were deduced by analyzing mutations in human FVIII which occurred naturally and which lead to a faster dissociation of the A2 domain associated with hemophilia. Such mutations result in differences between the two-stage assay as compared to the one-stage assay while determining FVIII clotting activity, whereas the two-stage assay result is lower than that of the one-stage assay as in the two-stage assay an incubation time of several minutes allows an unstable A2 domain to dissociate (Saenko et al., Vox Sang.,

83:89-96 (2002). It was inferred that in those cases where such an increased instability was the result of the introduction of a charged amino acid that amino acid should be mutated into one of the opposite charge. Examples for such mutations which lead to an improved FVIII with a plasma half life of its activated form of more than three minutes, preferably of more than 10 minutes, even more preferably more than 30 minutes, are listed in figure 3.

As a basis for introducing the mutations preferably a modified factor VIII cDNA is used which comprises a first DNA segment coding for the amino acids 1 through 740 of the human factor VIII and a second DNA segment coding for the amino acids 1649 through 2332 of the human factor VIII. These two segments may be interconnected by a linker DNA segment, but the invention also encompasses introducing the mutations into full length FVIII.
Subject of the invention is therefore a modified human factor VIII cDNA wherein mutations are inserted either in the wild-type factor VIII cDNA or in a factor VIII cDNA in which the B-domain is partially or completely deleted and may be replaced by a DNA linker segment, and

A) one or several codons of the human factor VIII cDNA which are not identical with the corresponding codon in the same position of the porcine factor VIII cDNA are substituted by a different codon in such a way that

- when the human sequence contains a codon for a neutral amino acid whereas the porcine sequence contains a codon for a charged amino acid then a codon for an amino acid with the same charge as found in the porcine sequence is introduced into the human sequence;

- when the human sequence contains a codon for a charged amino acid whereas the porcine sequence contains a codon for a neutral amino acid then a codon for a neutral amino acid or a codon for an amino acid of the opposite charge is introduced into the human sequence

- when the human sequence contains a codon for a charged amino acid whereas the porcine sequence contains a codon for an amino acid with the opposite charge then a codon for an amino acid with the opposite charge is introduced into the human sequence or

B) one or several codons for a charged amino acid which are found in the FVIII cDNA of a hemophilic patient are replaced by a codon for an amino acid of the opposite charge.

The production of factor VIII proteins at high levels in suitable host cells, requires the assembly of the above-mentioned modified factor VIII DNA's into efficient transcriptional units together with suitable regulatory elements in a recombinant expression vector, that can be propagated in E. coli according to methods known to those skilled in the art. Efficient transcriptional regulatory elements could be derived from viruses having animal cells as their natural hosts or from the chromosomal DNA of animal cells. Preferably, promoter-enhancer combinations derived from the Simian Virus 40, adenovirus, BK polyoma virus, human cytomegalovirus, or the long terminal repeat of Rous sarcoma virus, or promoter-enhancer combinations including strongly constitutively transcribed genes in animal cells like beta-actin or GRP78 can be used. In order to achieve stable high levels of mRNA transcribed from the factor VIII DNA's, the transcriptional unit should contain in its 3'-proximal part a DNA region encoding a transcriptional termination-polyadenylation sequence. Preferably, this sequence is derived from the Simian Virus 40 early transcriptional region, the rabbit beta-globin gene, or the human tissue plasminogen activator gene.

The factor VIII cDNA's are then integrated into the genome into a suitable host cell line for expression of the factor VIII proteins. Preferably this cell line should be an animal cell-line of vertebrate origin in order to ensure correct folding, disulfide bond formation, asparagines-linked glycosylation and other post-translational modifications as well as secretion into the cultivation medium. Examples on other

post-translational modifications are tyrosine O-sulfation, and proteolytic processing of the nascent polypeptide chain. Examples of cell lines that can be use are monkey COS-cells, mouse L-cells, mouse C127-cells, hamster BHK-21 cells, human embryonic kidney 293 cells, and preferentially CHO-cells.

The recombinant expression vector encoding the factor VIII cDNA's can be introduced into an animal cell line in several different ways. For instance, recombinant expression vectors can be created from vectors based on different animal viruses, Examples of these are vectors based on baculovirus, vaccinia virus, adenovirus, and preferably bovine papilloma virus.

The transcription units encoding the factor VIII DNA's can also be introduced into animal cells together with another recombinant gene which may function as a dominant selectable marker in these cells in order to facilitate the isolation of specific cell clones which have integrated the recombinant DNA into their genome. Examples of this type of dominant selectable marker genes are Tn5 aminoglycoside phosphotransferase, conferring resistance to Geneticin (G418), hygromycin phosphotransferase, conferring resistance to hygromycin, and puromycin acetyl transferase, conferring resistance to puromycin. The recombinant expression vector encoding such a selectable marker can reside either on the same vector as the one encoding the factor VIII cDNA, or it can be encoded on a separate vector which is simultaneously introduced and integrated to the genome of the host cell, frequently resulting in a tight physical linkage between the different transcription units.

Other types of selectable marker genes which can be used together with the factor VIII DNA's are based on various transcription units encoding dihydrofolate reductase (dhfr). After introduction of this type of gene into cells lacking endogenous dhfr-activity, preferentially CHO-cells (DUKX-B11, DG-44) it will enable these to grow in media lacking nucleosides. An example of such a medium is Ham's F12 without hypoxanthin, thymidin, and glycine. These dhfr-genes can be introduced together with the factor VIII cDNA transcriptional units into CHO-cells of

the above type, either linked on the same vector or on different vectors, thus creating dhfr-positive cell lines producing recombinant factor VIII protein.

If the above cell lines are grown in the presence of the cytotoxic dhfr-inhibitor methotrexate, new cell lines resistant to methotrexate will emerge. These cell lines may produce recombinant factor VIII protein at an increased rate due to the amplified number of linked dhfr and factor VIII transcriptional units. When propagating these cell lines in increasing concentrations of methotrexate (1-10000 nM), new cell lines can be obtained which produce factor VIII protein at very high rate.

The above cell lines producing factor VIII protein can be grown on a large scale, either in suspension culture or on various solid supports. Examples of these supports are microcarriers based on dextran or collagen matrices, or solid supports in the form of hollow fibres or various ceramic materials. When grown in cell suspension culture or on microcarriers the culture of the above cell lines can be performed either as a bath culture or as a perfusion culture with continuous production of conditioned medium over extended periods of time. Thus, according to the present invention, the above cell lines are well suited for the development of an industrial process for the production of recombinant factor VIII that can be isolated from human plasma.

The recombinant factor VIII protein which accumulate in the medium of CHO-cells of the above type, can be concentrated and purified by a variety of biochemical and chromatographic methods, including methods utilizing differences in size, charge, hydrophobicity, solubility, specific affinity, etc. between the recombinant factor VIII protein and other substances in the cell cultivation medium.

An example of such a purification is the adsorption of the recombinant factor VIII protein to a monoclonal antibody which is immobilised on a solid support. After

desorption, the factor VIII protein can be further purified by a variety of chromatographic techniques based on the above properties.

The recombinant proteins with factor VIII activity described in this invention can be formulated into pharmaceutical preparations for therapeutic use. The purified factor VIII proteins may be dissolved in conventional physiologically compatible aqueous buffer solutions to which there may be added, optionally, pharmaceutical adjuvants to provide pharmaceutical preparations.

The modified factor VIII DNA's of this invention may also be integrated into a transfer vector for use in the human gene therapy.

A further subject of this invention is a modified biologically active recombinant human factor VIII with improved plasma half life of its activated form wherein mutations are inserted either in the wild-type factor VIII or in a FVIII in which the B-domain is partially or completely deleted and replaced by a linker, and

A) one or several amino acids of the human factor VIII which are not identical with the corresponding amino acid in the same position of the porcine factor VIII are substituted by a different amino acid in such a way that

- when the human sequence contains a neutral amino acid whereas the porcine sequence contains a charged amino acid then a charged amino acid with the same charge as found in the porcine sequence is introduced into the human sequence;

- when the human sequence contains a charged amino acid whereas the porcine sequence contains a neutral amino acid then a neutral amino acid or an amino acid of the opposite charge is introduced into the human sequence;

- when the human sequence contains a charged amino acid whereas the porcine sequence contains an amino acid with the opposite charge then an amino acid with the opposite charge is introduced into the human sequence or

B) one or several charged amino acids which are found in the FVIII amino sequence of hemophilic patients are replaced by a codon for an amino acid of the opposite charge.

The present invention will be further described more in detail in the following examples thereof. This description of specific embodiments of the invention will be made in conjunction with the appended figures.

**Generation of FVIII mutants**

For the generation of FVIII mutants, a suitable subfragment of the FVIII cDNA (e.g. AvaI - SacI, encompassing aminoacids 226 to 978) is first subcloned into a suitable cloning vector to reduce subsequent sequencing efforts. Site directed mutagenesis is then performed with a commercially available mutagenesis kit (e.g. QuickChange SiteDirected Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. Primers used for mutagenesis are listed in the attached sequence listing and below, where the mutagenic bases are indicated in bold letters.

Mutation: A284K

Forward primer

$^{5'}$GGAACCATCGCCAG**AA**GTCCTTGGAAATCTCGCC$^{3'}$ (Sequence 1)

Reverse primer

$^{5'}$GGCGAGATTTCCAAGGAC**TT**CTGGCGATGGTTCC$^{3'}$ (Sequence 2)

Mutation: D318G

Forward primer

$^{5'}$CCCACCAACATG**GT**GGCATGGAAGCTTATGTC$^{3'}$ (Sequence 3)

Reverse primer
5'GACATAAGCTTCCATGCC**AC**CATGTTGGTGGG3' (Sequence 4)

Mutation: M337R
Forward primer
5'CAGAGGAACCCCAACTACGA**CGT**AAAAATAATGAAGAAGCGGAAGAC3'
(Sequence 5)
Reverse primer
5'GTCTTCCGCTTCTTCATTATTTTT**ACG**TCGTAGTTGGGGTTCCTCTG3'
(Sequence 6)

Mutation: N340D
Forward primer
5'CCCAACTACGAATGAAAAAT**G**ATGAAGAAGCGGAAGACTATG3'
(Sequence 7)
Reverse primer
5'CATAGTCTTCCGCTTCTTCAT**C**ATTTTTCATTCGTAGTTGGG3'
(Sequence 8)

Mutation: D349N
Forward primer
5'GAAGAAGCGGAAGACTATGATGAT**A**ATCTTACTGATTCTG3'
(Sequence 9)
Reverse primer 5'CAGAATCAGTAAGAT**T**ATCATCATAGTCTTCCGCTTCTTC3'
(Sequence 10)

Mutation: N364D
Forward primer 5'GGTCAGGTTTGATGATGAC**G**ACTCTCCTTCCTTTATCC3'
(Sequence 11)
Reverse primer 5'GGATAAAGGAAGGAGAGT**C**GTCATCATCAAACCTGACC3'
(Sequence 12)

Mutation: D403S

Forward primer $^{5'}$CCCTTAGTCCTCGCCCCC**TC**TGACAGAAGTTATAAAAG$^{3'}$ (Sequence 13)

Reverse primer $^{5'}$CTTTTATAACTTCTGTCA**GA**GGGGGCGAGGACTAAGGG$^{3'}$ (Sequence 14)

Mutation: E434V

Forward primer $^{5'}$GTCCGATTTATGGCATACACAGATG**TT**ACCTTTAAGACTCG$^{3'}$ (Sequence 15)

Reverse primer $^{5'}$CGAGTCTTAAAGGT**AA**CATCTGTGTATGCCATAAATCGGAC$^{3'}$ (Sequence 16)

Mutation: E440K

Forward primer $^{5'}$CCTTTAAGACTCGT**A**AAGCTATTCAGCATGAATCAGG$^{3'}$ (Sequence 17)

Reverse primer $^{5'}$CCTGATTCATGCTGAATAGCTTT**T**ACGAGTCTTAAAGG$^{3'}$ (Sequence 18)

Mutation: Q468K

Forward primer $^{5'}$CACACTGTTGATTATATTTAAGAAT**A**AAGCAAGCAGACCATATAAC$^{3'}$ (Sequence 19)

Reverse primer $^{5'}$GTTATATGGTCTGCTTGCTTTATTCTTAAATATAATCAACAGTGTG$^{3'}$ (Sequence 20)

Mutation: R484S

Forward primer
5'CCCTCACGGAATCACTGATGTCTCTCCTTTGTATTCAAGG3'
(Sequence 21)
Reverse primer
5'CCTTGAATACAAAGGAGAGACATCAGTGATTCCGTGAGGG3'
(Sequence 22)

Mutation: R489G
Forward primer 5'GATGTCCGTCCTTTGTATTCAGGGAGATTACCAAAAGG3'
(Sequence 23)
Reverse primer 5'CCTTTTGGTAATCTCCCTGAATACAAAGGACGGACATC3'
(Sequence 24)

Mutation: R583Q
Forward primer
5'CTGTATTTGATGAGAACCAAAGCTGGTACCTCACAG3' (Sequence 25)
Reverse primer
5'CTGTGAGGTACCAGCTTTGGTTCTCATCAAATACAG3' (Sequence 26)

Mutation: A599D
Forward primer
5'CTCCCCAATCCAGATGGAGTGCAGCTTGAG3' (Sequence 27)
Reverse primer
5'CTCAAGCTGCACTCCATCTGGATTGGGGAG3' (Sequence 28)

Mutation: E604Q
Forward primer
5'CAGCTGGAGTGCAGCTTCAGGATCCAGAGTTC3' (Sequence 29)
Reverse primer
5'GAACTCTGGATCCTGAAGCTGCACTCCAGCTG3' (Sequence 30)

Mutation: G1948K

Forward primer

5'CGATGGTATCTGCTCAGCATG**AAG**AGCAATGAAAACATCCATTCTATT C3' (Sequence 31)

Reverse primer

5'GAATAGAATGGATGTTTTCATTGCT**CTT**CATGCTGAGCAGATACCATCG 3' (Sequence 32)

After clone isolation and sequence verification mutant subfragments are reinserted into the respective expression vector.

**Expression of FVIII mutants**

Transfection of FVIII mutant clones and expression of the mutant FVIII molecules is done as described previously and known to those skilled in the art (e.g. Plantier JL et al. Thromb. Haemost. 86:596-603 (2001)).

**Measuring affinity of A2 subunit for A1/A3-C1-C2**

The increased affinity of the A2 subunit for the A1/A3-C1-C2 can be measured as previously described by functional assays (Fay PJ & Smudzin TM. J. Biol. Chem. 267:13246-50 (1992); Lollar P et al. J. Biol. Chem. 267:23652-57 (1992)) as well as a physical assay employing surface plasmon resonance (Persson E et al. Biochemistry 34:12775-81 (1995)).

The sequence of the porcine factor VIII is shown in Sequence 33, whereas the sequence of the human factor VIII is shown in sequence 34 of the attached sequence listing.

Fig. 1: Comparison of porcine to human FVIII protein sequence (numbers refer to mature human FVIII; in the porcine sequence, only discrepant aminoacids are displayed; identical aminoacids are indicated by a ".")

```
241  . . . . . K . . . . . .  Porcine FVIII
240  R S L P G L I G C H R K S V Y W H V I G  Human FVIII

261  . . . S . . . . . . . . . . . . . . .  Porcine FVIII
260  M G T T P E V H S I F L E G H T F L V R  Human FVIII

281  H . . . . . L . . . . . F  Porcine FVIII
280  N H R Q A S L E I S P I T F L T A Q T L  Human FVIII

301  . . . . . H . G .  Porcine FVIII
300  L M D L G Q F L L F C H I S S H Q H D G  Human FVIII

321  . . . H . R . E . . A . . . . . R . A  Porcine FVIII
320  M E A Y V K V D S C P E E P Q L R M K N  Human FVIII

341  D . . - . . . . . N . Y . . D . . . . .  Porcine FVIII
340  N E E A E D Y D D D L T D S E M D V V R  Human FVIII

360  L . G . D V S P . . . . . .  Porcine FVIII
360  F D D D N S P S F I Q I R S V A K K H P  Human FVIII

380  . . . . . S . . . . . A .  Porcine FVIII
380  K T W V H Y I A A E E E D W D Y A P L V  Human FVIII

400  P S . S . . . . . L . . . S . . . . .  Porcine FVIII
400  L A P D D R S Y K S Q Y L N N G P Q R I  Human FVIII

420  . . . . . A . . V . . . . V . . . . .  Porcine FVIII
420  G R K Y K K V R F M A Y T D E T F K T R  Human FVIII

440  K . . P Y . . . . . .  Porcine FVIII
440  E A I Q H E S G I L G P L L Y G E V G D  Human FVIII

460  . . . . . K . . . . . .  Porcine FVIII
460  T L L I I F K N Q A S R P Y N I Y P H G  Human FVIII

480  . . . . S A . H P G . . L . . W . . . .  Porcine FVIII
480  I T D V R P L Y S R R L P K G V K H L K  Human FVIII

500  . M . . . . . T . . . . . .  Porcine FVIII
500  D F P I L P G E I F K Y K W T V T V E D  Human FVIII

520  . . . . . S I . L  Porcine FVIII
520  G P T K S D P R C L T R Y Y S S F V N M  Human FVIII

540  . K . . . . . .  Porcine FVIII
540  E R D L A S G L I G P L L I C Y K E S V  Human FVIII

560  . . . . . M . . . . . .  Porcine FVIII
560  D Q R G N Q I M S D K R N V I L F S V F  Human FVIII

580  . . . Q . . . . . A . . . . . D  Porcine FVIII
580  D E N R S W Y L T E N I Q R F L P N P A  Human FVIII

600  . L . P Q . . . . . .  Porcine FVIII
600  G V Q L E D P E F Q A S N I M H S I N G  Human FVIII
```

**Fig. 2:** **Mutations of human FVIII which are based on a protein comparison with porcine FVIII (does not comprise all mutations which are possible according to the invention):**

| aa (mature human FVIII) | Amino acid in human sequence | Mutated to | Or mutated to |
|---|---|---|---|
| 318 | D | G | K |
| 337 | M | R | |
| 340 | N | D | |
| 349 | D | N | K |
| 364 | N | D | |
| 403 | D | S | K |
| 434 | E | V | K |
| 440 | E | K | |
| 468 | Q | K | |
| 484 | R | S | E |
| 489 | R | G | E |
| 583 | R | Q | E |
| 599 | A | D | |
| 604 | E | Q | K |

**Fig. 3: Mutations of human FVIII which are based on an analysis of existing human mutations leading to an enhanced dissociation of the A2 domain (does not comprise all mutations possible according to the invention)**

| aa (Mature human FVIII) | From (human sequence) | To | Comments |
|---|---|---|---|
| 284 | A | K | A to E leads to enhanced dissociation of A2 domain |
| 1948 | G | K | G to D leads to enhanced dissociation of A2 domain |

In the following Sequence Listing Sequences 1-32 describe oligonucleotides which are used to introduce specific mutations into FVIII. Sequence 33 is the amino acid sequence of full length mature porcine FVIII, Sequence 34 is the amino acid sequence of full length mature human FVIII.

Sequence Listing

Organization Applicant

---

Street : Emil-von-Behring-Straße 76
City : Marburg
State : Hessen
Country : Germany
PostalCode : 35041
PhoneNumber : 0049-6421-39 45 06
FaxNumber : 0049-6421-39 45 58
EmailAddress : Hugo.Pfeil@aventis.com
<110> OrganizationName : Aventis Behring GmbH

Application Project

---

<120> Title : Modified cDNA Factor VIII and its Derivatives
<130> AppFileReference : 2002/M018 (A66)
<140> CurrentAppNumber :
<141> CurrentFilingDate : ____-__-__

Sequence

---

<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ggaaccatcg ccagaagtcc ttggaaatct cgcc 34
<212> Type : DNA
<211> Length : 34
SequenceName : Sequenz 1
SequenceDescription :

Feature

---

Sequence: Sequenz 1:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 34
Other Information :
CDSJoin : No

Custom Codon
Sequence Name : Sequenz 1

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ggcgagattt ccaaggactt ctggcgatgg ttcc 34
<212> Type : DNA
<211> Length : 34
SequenceName : Sequenz 2
SequenceDescription :

Feature
---
Sequence: Sequenz 2:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 34
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 2

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
cccaccaaca tggtggcatg gaagcttatg tc 32
<212> Type : DNA
<211> Length : 32
SequenceName : Sequenz 3
SequenceDescription :

Feature
---

Sequence: Sequenz 3:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 32
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 3

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
gacataagct tccatgccac catgttggtg gg 32
<212> Type : DNA
<211> Length : 32
SequenceName : Sequenz 4
SequenceDescription :

Feature
---
Sequence: Sequenz 4:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 32
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 4

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :

cagaggaacc ccaactacga cgtaaaaata atgaagaagc ggaagac 47

<212> Type : DNA

<211> Length : 47

SequenceName : Sequenz 5

SequenceDescription :

Feature

---

Sequence: Sequenz 5:

<221> FeatureKey : primer_bind

<222> LocationFrom : 1

<222> LocationTo : 47

Other Information :

CDSJoin : No

Custom Codon

---

Sequence Name : Sequenz 5

Sequence

---

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :

gtcttccgct tcttcattat ttttacgtcg tagttggggt tcctctg 47

<212> Type : DNA

<211> Length : 47

SequenceName : Sequenz 6

SequenceDescription :

Feature

---

Sequence: Sequenz 6:

<221> FeatureKey : primer_bind

<222> LocationFrom : 1

<222> LocationTo : 47

Other Information :

CDSJoin : No

Custom Codon

---

Sequence Name : Sequenz 6

Sequence

---

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :

cccaactacg aatgaaaaat gatgaagaag cggaagacta tg 42

<212> Type : DNA

<211> Length : 42

SequenceName : Sequenz 7

SequenceDescription :

Feature

---

Sequence: Sequenz 7:

<221> FeatureKey : primer_bind

<222> LocationFrom : 1

<222> LocationTo : 42

Other Information :

CDSJoin : No

Custom Codon

---

Sequence Name : Sequenz 7

Sequence

---

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :

catagtcttc cgcttcttca tcatttttca ttcgtagttg gg 42

<212> Type : DNA

<211> Length : 42

SequenceName : Sequenz 8

SequenceDescription :

Feature

```
-------
Sequence: Sequenz 8:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 42
      Other Information :
      CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 8

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
gaagaagcgg aagactatga tgataatctt actgattctg                    40
<212> Type : DNA
<211> Length : 40
      SequenceName : Sequenz 9
      SequenceDescription :

Feature
-------
Sequence: Sequenz 9:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 40
      Other Information :
      CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 9

Sequence
--------
<213> OrganismName : Artificial Sequence
```

<400> PreSequenceString :
cagaatcagt aagattatca tcatagtctt ccgcttcttc 40
<212> Type : DNA
<211> Length : 40
SequenceName : Sequenz 10
SequenceDescription :

Feature
---
Sequence: Sequenz 10:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 40
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 10

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ggtcaggttt gatgatgacg actctccttc ctttatcc 38
<212> Type : DNA
<211> Length : 38
SequenceName : Sequenz 11
SequenceDescription :

Feature
---
Sequence: Sequenz 11:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 38
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 11

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ggataaagga aggagagtcg tcatcatcaa acctgacc 38
<212> Type : DNA
<211> Length : 38
SequenceName : Sequenz 12
SequenceDescription :

Feature
---
Sequence: Sequenz 12:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 38
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 12

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
cccttagtcc tcgccccctc tgacagaagt tataaaag 38
<212> Type : DNA
<211> Length : 38
SequenceName : Sequenz 13
SequenceDescription :

```
Feature
-------
Sequence: Sequenz 13:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 38
      Other Information :
      CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 13

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
cttttataac ttctgtcaga gggggcgagg actaaggg                    38
<212> Type : DNA
<211> Length : 38
      SequenceName : Sequenz 14
      SequenceDescription :

Feature
-------
Sequence: Sequenz 14:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 38
      Other Information :
      CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 14

Sequence
--------
```

<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
gtccgattta tggcatacac agatgttacc tttaagactc g 41
<212> Type : DNA
<211> Length : 41
SequenceName : Sequenz 15
SequenceDescription :

Feature
---
Sequence: Sequenz 15:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 41
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 15

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
cgagtcttaa aggtaacatc tgtgtatgcc ataaatcgga c 41
<212> Type : DNA
<211> Length : 41
SequenceName : Sequenz 16
SequenceDescription :

Feature
---
Sequence: Sequenz 16:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 41
Other Information :

CDSJoin : No

Custom Codon

---

Sequence Name : Sequenz 16

Sequence

---

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :

cctttaagac tcgtaaagct attcagcatg aatcagg 37

<212> Type : DNA

<211> Length : 37

SequenceName : Sequenz 17

SequenceDescription :

Feature

---

Sequence: Sequenz 17:

<221> FeatureKey : primer_bind

<222> LocationFrom : 1

<222> LocationTo : 37

Other Information :

CDSJoin : No

Custom Codon

---

Sequence Name : Sequenz 17

Sequence

---

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :

cctgattcat gctgaatagc tttacgagtc ttaaagg 37

<212> Type : DNA

<211> Length : 37

SequenceName : Sequenz 18

SequenceDescription :

Feature
-------
Sequence: Sequenz 18:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 37
Other Information :
CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 18

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
cacactgttg attatattta agaataaagc aagcagacca tataac 46
<212> Type : DNA
<211> Length : 46
SequenceName : Sequenz 19
SequenceDescription :

Feature
-------
Sequence: Sequenz 19:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 46
Other Information :
CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 19

Sequence

--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
gttatatggt ctgcttgctt tattcttaaa tataatcaac agtgtg 46
<212> Type : DNA
<211> Length : 46
SequenceName : Sequenz 20
SequenceDescription :

Feature
-------
Sequence: Sequenz 20:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 46
Other Information :
CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 20

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ccctcacgga atcactgatg tctctccttt gtattcaagg 40
<212> Type : DNA
<211> Length : 40
SequenceName : Sequenz 21
SequenceDescription :

Feature
-------
Sequence: Sequenz 21:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 40

Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 21

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ccttgaatac aaaggagaga catcagtgat tccgtgaggg 40
<212> Type : DNA
<211> Length : 40
SequenceName : Sequenz 22
SequenceDescription :

Feature
---
Sequence: Sequenz 22:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 40
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 22

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
gatgtccgtc ctttgtattc agggagatta ccaaaagg 38
<212> Type : DNA
<211> Length : 38
SequenceName : Sequenz 23

SequenceDescription :

Feature
-------
Sequence: Sequenz 23:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 38
Other Information :
CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 23

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
cctttggta atctccctga atacaaagga cggacatc 38
<212> Type : DNA
<211> Length : 38
SequenceName : Sequenz 24
SequenceDescription :

Feature
-------
Sequence: Sequenz 24:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 38
Other Information :
CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 24

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ctgtatttga tgagaaccaa agctggtacc tcacag 36
<212> Type : DNA
<211> Length : 36
SequenceName : Sequenz 25
SequenceDescription :

Feature
-------
Sequence: Sequenz 25:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 36
Other Information :
CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 25

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ctgtgaggta ccagctttgg ttctcatcaa atacag 36
<212> Type : DNA
<211> Length : 36
SequenceName : Sequenz 26
SequenceDescription :

Feature
-------
Sequence: Sequenz 26:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1

<222> LocationTo : 36
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 26

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ctccccaatc cagatggagt gcagcttgag 30
<212> Type : DNA
<211> Length : 30
SequenceName : Sequenz 27
SequenceDescription :

Feature
---
Sequence: Sequenz 27:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 30
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 27

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
ctcaagctgc actccatctg gattggggag 30
<212> Type : DNA
<211> Length : 30

SequenceName : Sequenz 28
SequenceDescription :

Feature
---
Sequence: Sequenz 28:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 30
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 28

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
cagctggagt gcagcttcag gatccagagt tc 32
<212> Type : DNA
<211> Length : 32
SequenceName : Sequenz 29
SequenceDescription :

Feature
---
Sequence: Sequenz 29:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 32
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 29

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
gaactctgga tcctgaagct gcactccagc tg 32
<212> Type : DNA
<211> Length : 32
SequenceName : Sequenz 30
SequenceDescription :

Feature
-------
Sequence: Sequenz 30:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 32
Other Information :
CDSJoin : No

Custom Codon
------------
Sequence Name : Sequenz 30

Sequence
--------
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
cgatggtatc tgctcagcat gaagagcaat gaaaacatcc attctattc 49
<212> Type : DNA
<211> Length : 49
SequenceName : Sequenz 31
SequenceDescription :

Feature
-------
Sequence: Sequenz 31:
<221> FeatureKey : primer_bind

<222> LocationFrom : 1
<222> LocationTo : 49
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 31

Sequence
---
<213> OrganismName : Artificial Sequence
<400> PreSequenceString :
gaatagaatg gatgttttca ttgctcttca tgctgagcag ataccatcg 49
<212> Type : DNA
<211> Length : 49
SequenceName : Sequenz 32
SequenceDescription :

Feature
---
Sequence: Sequenz 32:
<221> FeatureKey : primer_bind
<222> LocationFrom : 1
<222> LocationTo : 49
Other Information :
CDSJoin : No

Custom Codon
---
Sequence Name : Sequenz 32

Sequence
---
<213> OrganismName : Porcine
<400> PreSequenceString :
AIRRYYLGAV ELSWDYRQSE LLRELHVDTR FPATAPGALP LGPSVLYKKT VFVEFTDQLF 60

SVARPRPPWM GLLGPTIQAE VYDTVVVTLK NMASHPVSLH AVGVSFWKSS EGAEYEDHTS 120

QREKEDDKVL PGKSQTYVWQ VLKENGPTAS DPPCLTYSYL SHVDLVKDLN SGLIGALLVC 180

REGSLTRERT QNLHEFVLLF AVFDEGKSWH SARNDSWTRA MDPAPARAQP AMHTVNGYVN 240

RSLPGLIGCH KKSVYWHVIG MGTSPEVHSI FLEGHTFLVR HHRQASLEIS PLTFLTAQTF 300

LMDLGQFLLF CHISSHHHGG MEAHVRVESC AEEPQLRRKA DEEEDYDDNL YDSDMDVVRL 360

DGDDVSPFIQ IRSVAKKHPK TWVHYISAEE EDWDYAPAVP SPSDRSYKSL YLNSGPQRIG 420

RKYKKARFVA YTDVTFKTRK AIPYESGILG PLLYGEVGDT LLIIFKNKAS RPYNIYPHGI 480

TDVSALHPGR LLKGWKHLKD MPILPGETFK YKWTVTVEDG PTKSDPRCLT RYYSSSINLE 540

KDLASGLIGP LLICYKESVD QRGNQMMSDK RNVILFSVFD ENQSWYLAEN IQRFLPNPDG 600

LQPQDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SVGAQTDFLS VFFSGYTFKH 660

KMVYEDTLTL FPFSGETVFM SMENPGLWVL GCHNSDLRNR GMTALLKVYS CDRDIGDYYD 720

NTYEDIPGFL LSGKNVIEPR SFAQNSRPPS ASQKQFQTIT SPEDDVELDP QSGERTQALE 780

ELSVPSGDGS MLLGQNPAPH GSSSSDLQEA RNEADDYLPG ARERNTAPSA AARLRPELHH 840

SAERVLTPEP EKELKKLDSK MSSSSDLLKT SPTIPSDTLS AETERTHSLG PPHPQVNFRS 900

QLGAIVLGKN SSHFIGAGVP LGSTEEDHES SLGENVSPVE SDGIFEKERA HGPASLTKDD 960

VLFKVNISLV KTNKARVYLK TNRKIHIDDA ALLTENRASA TFMDKNTTAS GLNHVSNWIK 1020

GPLGKNPLSS ERGPSPELLT SSGSGKSVKG QSSGQGRIRV AVEEEELSKG KEMMLPNSEL 1080

TFLTNSADVQ GNDTHSQGKK SREEMERREK LVQEKVDLPQ VYTATGTKNF LRNIFHQSTE 1140

PSVEGFDGGS HAPVPQDSRS LNDSAERAET HIAHFSAIRE EAPLEAPGNR TGPGPRSAVP 1200

RRVKQSLKQI RLPLEEIKPE RGVVLNATST RWSESSPILQ GAKRNNLSLP FLTLEMAGGQ 1260

GKISALGKSA AGPLASGKLE KAVLSSAGLS EASGKAEFLP KVRVHREDLL PQKTSNVSCA 1320

HGDLGQEIFL QKTRGPVNLN KVNRPGRTPS KLLGPPMPKE WESLEKSPKS TALRTKDIIS 1380

LPLDRHESNH SIAAKNEGQA ETQREAAWTK QGGPGRLCAP KPPVLRRHQR DISLPTFQPE 1440

EDKMDYDDIF STETKGEDFD IYGEDENQDP RSFQKRTRHY FIAAVEQLWD YGMSESPRAL 1500

RNRAQNGEVP RFKKVVFREF ADGSFTQPSY RGELNKHLGL LGPYIRAEVE DNIMVTFKNQ 1560

ASRPYSFYSS LISYPDDQEQ GAEPRHNFVQ PNETRTYFWK VQHHMAPTED EFDCKAWAYF 1620

SDVDLEKDVH SGLIGPLLIC RANTLNAAHG RQVTVQEFAL FFTIFDETKS WYFTENVERN 1680

CRAPCHLQME DPTLKENYRF HAINGYVMDT LPGLVMAQNQ RIRWYLLSMG SNENIHSIHF 1740

SGHVFSVRKK EEYKMAVYNL YPGVFETVEM LPSKVGIWRI ECLIGEHLQA GMSTTFLVYS 1800

KECQAPLGMA SGRIRDFQIT ASGQYGQWAP KLARLHYSGS INAWSTKDPH SWIKVDLLAP 1860

MIIHGIMTQG ARQKFSSLYI SQFIIMYSLD GRNWQSYRGN STGTLMVFFG NVDASGIKHN 1920

IFNPPIVARY IRLHPTHYSI RSTLRMELMG CDLNSCSMPL GMQNKAISDS QITASSHLSN 1980

IFATWSPSQA RLHLQGRTNA WRPRVSSAEE WLQVDLQKTV KVTGITTQGV KSLLSSMYVK 2040

EFLVSSSQDG RRWTLFLQDG HTKVFQGNQD SSTPVVNALD PPLFTRYLRI HPTSWAQHIA 2100

LRLEVLGCEA QDLY 2114

<212> Type : PRT

<211> Length : 2114

SequenceName : Sequenz 33

SequenceDescription :

Feature

---

Sequence: Sequenz 33:
<221> FeatureKey : CHAIN
<222> LocationFrom : 1
<222> LocationTo : 2114
Other Information :
CDSJoin : No

Sequence
---
<213> OrganismName : human
<400> PreSequenceString :

ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL FVEFTDHLFN 60

IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA VGVSYWKASE GAEYDDQTSQ 120

REKEDDKVFP GGSHTYVWQV LKENGPMASD PLCLTYSYLS HVDLVKDLNS GLIGALLVCR 180

EGSLAKEKTQ TLHKFILLFA VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR 240

SLPGLIGCHR KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300

MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL TDSEMDVVRF 360

DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL APDDRSYKSQ YLNNGPQRIG 420

RKYKKVRFMA YTDETFKTRE AIQHESGILG PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI 480

TDVRPLYSRR LPKGVKHLKD FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME 540

RDLASGLIGP LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600

VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS VFFSGYTFKH 660

KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR GMTALLKVSS CDKNTGDYYE 720

DSYEDISAYL LSKNNAIEPR SFSQNSRHRS TRQKQFNATT IPENDIEKTD PWFAHRTPMP 780

KIQNVSSSDL LMLLRQSPTP HGLSLSDLQE AKYETFSDDP SPGAIDSNNS LSEMTHFRPQ 840

LHHSGDMVFT PESGLQLRLN EKLGTTAATE LKKLDFKVSS TSNNLISTIP SDNLAAGTDN 900

TSSLGPPSMP VHYDSQLDTT LFGKKSSPLT ESGGPLSLSE ENNDSKLLES GLMNSQESSW 960

GKNVSSTESG RLFKGKRAHG PALLTKDNAL FKVSISLLKT NKTSNNSATN RKTHIDGPSL 1020

LIENSPSVWQ NILESDTEFK KVTPLIHDRM LMDKNATALR LNHMSNKTTS SKNMEMVQQK 1080

KEGPIPPDAQ NPDMSFFKML FLPESARWIQ RTHGKNSLNS GQGPSPKQLV SLGPEKSVEG 1140

QNFLSEKNKV VVGKGEFTKD VGLKEMVFPS SRNLFLTNLD NLHENNTHNQ EKKIQEEIEK 1200

KETLIQENVV LPQIHTVTGT KNFMKNLFLL STRQNVEGSY DGAYAPVLQD FRSLNDSTNR 1260

TKKHTAHFSK KGEEENLEGL GNQTKQIVEK YACTTRISPN TSQQNFVTQR SKRALKQFRL 1320

PLEETELEKR IIVDDTSTQW SKNMKHLTPS TLTQIDYNEK EKGAITQSPL SDCLTRSHSI 1380

PQANRSPLPI AKVSSFPSIR PIYLTRVLFQ DNSSHLPAAS YRKKDSGVQE SSHFLQGAKK 1440

NNLSLAILTL EMTGDQREVG SLGTSATNSV TYKKVENTVL PKPDLPKTSG KVELLPKVHI 1500

YQKDLFPTET SNGSPGHLDL VEGSLLQGTE GAIKWNEANR PGKVPFLRVA TESSAKTPSK 1560

LLDPLAWDNH YGTQIPKEEW KSQEKSPEKT AFKKKDTILS LNACESNHAI AAINEGQNKP 1620

EIEVTWAKQG RTERLCSQNP PVLKRHQREI TRTTLQSDQE EIDYDDTISV EMKKEDFDIY 1680

DEDENQSPRS FQKKTRHYFI AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD 1740

GSFTQPLYRG ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800

EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG LIGPLLVCHT 1860

NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR APCNIQMEDP TFKENYRFHA 1920

INGYIMDTLP GLVMAQDQRI RWYLLSMGSN ENIHSIHFSG HVFTVRKKEE YKMALYNLYP 1980

GVFETVEMLP SKAGIWRVEC LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS 2040

GQYGQWAPKL ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100

FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR LHPTHYSIRS 2160

TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF ATWSPSKARL HLQGRSNAWR 2220

PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV 2280

KVFQGNQDSF TPVVNSLDPP LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY 2332

<212> Type : PRT
<211> Length : 2332
SequenceName : Sequenz 34
SequenceDescription :

Feature
---

Sequence: Sequenz 34:
<221> FeatureKey : CHAIN
<222> LocationFrom : 1
<222> LocationTo : 2332
Other Information :
CDSJoin : No

**Aventis Behring GmbH** **2002/M018 (A66)**
**ANR 8177007** **Dr. Pfe/ns**

**Claims:**

1. Modified human factor VIII cDNA wherein mutations are inserted either in the wild-type factor VIII cDNA or in a factor VIII cDNA in which the B-domain is partially or completely deleted and may be replaced by a DNA linker segment, **characterised in that**

A) one or several codons of the human factor VIII cDNA which are not identical with the corresponding codon in the same position of the porcine factor VIII cDNA are substituted by a different codon in such a way that

- when the human sequence contains a codon for a neutral amino acid whereas the porcine sequence contains a codon for a charged amino acid then a codon for an amino acid with the same charge as found in the porcine sequence is introduced into the human sequence;

- when the human sequence contains a codon for a charged amino acid whereas the porcine sequence contains a codon for a neutral amino acid then a codon for a neutral amino acid or a codon for an amino acid of the opposite charge is introduced into the human sequence,

- when the human sequence contains a codon for a charged amino acid whereas the porcine sequence contains a codon for an amino acid with the opposite charge then a codon for an amino acid with the opposite charge is introduced into the human sequence or

B) one or several codons for a charged amino acid which are found in the FVIII cDNA of a hemophilic patient are replaced by a codon for an amino acid of the opposite charge.

2. Recombinant expression vector containing the factor VIII cDNA as claimed in claim 1, **characterised in that** it carries in addition transcriptional regulatory elements for expression in a suitable host cell.

3. Modified biologically active recombinant human factor VIII with improved stability wherein mutations are inserted either in the wild-type factor VIII or in a factor VIII in which the B-domain is partially or completely deleted and may be replaced by a linker, **characterised in that**

A.) one or several amino acids of the human factor VIII which are not identical with the corresponding amino acid in the same position of the porcine factor VIII are substituted by a different amino acid in such a way that

- when the human sequence contains a neutral amino acid whereas the porcine sequence contains a charged amino acid then a charged amino acid with the same charge as found in the porcine sequence is introduced into the human sequence;

- when the human sequence contains a charged amino acid whereas the porcine sequence contains a neutral amino acid then a neutral amino acid or an amino acid of the opposite charge is introduced into the human sequence;

- when the human sequence contains a charged amino acid whereas the porcine sequence contains an amino acid with the opposite charge then an amino acid with the opposite charge is introduced into the human sequence or

B) one or several charged amino acids which are found in the FVIII amino sequence of hemophilic patients are replaced by a codon for an amino acid of the opposite charge.

4. Modified biologically active recombinant human factor VIII as claimed in claim 3, wherein the plasma half life of its activated form is more than 3 minutes, preferably more than 10 minutes and most preferably more than 30 minutes.

5. Modified human factor VIII, **characterised in that** its A2-domain is stabilised by the substitution of one or several amino acids as claimed in claim 3.

6. Process for the recombinant production of a modified human factor VIII as claimed in claim 3 either in cell suspension or on a solid support as a bath cell culture or as a perfusion cell culture with continuous production of a conditioned medium **characterised in that** the factor VIII proteins, which are expressed by a suitable host cell line are purified by chromatographic methods.

7. Process as claimed in claim 6, **characterised in that** the transcription units encoding the modified factor VIII cDNA of claims 1 and 2 contain a dominant selectable marker in order to facilitate the isolation of specific cell clones which have integrated said specific c-DNA into their genome.

8. Host cell line for expression of the factor VIII proteins of claim 3, **characterised in that** it is an animal cell line of vertebrate origin which contains the factor VIII cDNA of claim 1 integrated into its genome.

9. Pharmaceutical composition, **characterised in that it** comprises a modified biologically active recombinant human factor VIII of claim 3.

10. Vector for gene therapy of hemophilia A, characterized in that it contains a modified FVIII cDNA as claimed in claim 1.

**Aventis Behring GmbH**
**ANR 8177007**

**2002/M018 (A66)**
**Dr. Pfe/ns**

Abstract:

**Modified cDNA Factor VIII and its Derivatives**

Modified human factor VIII cDNA wherein mutations are inserted either in the wild-type factor VIII cDNA or in a factor VIII cDNA in which the B-domain is partially or completely deleted and may be replaced by a DNA linker segment and

A) one or several codons of the human factor VIII cDNA which are not identical with the corresponding codon in the same position of the porcine factor VIII cDNA are substituted by a different codon in such a way that

- when the human sequence contains a codon for a neutral amino acid whereas the porcine sequence contains a codon for a charged amino acid then a codon for an amino acid with the same charge as found in the porcine sequence is introduced into the human sequence;

- when the human sequence contains a codon for a charged amino acid whereas the porcine sequence contains a codon for a neutral amino acid then a codon for a neutral amino acid or a codon for an amino acid of the opposite charge is introduced into the human sequence,
- when the human sequence contains a codon for a charged amino acid whereas the porcine sequence contains a codon for an amino

acid with the opposite charge then a codon for an amino acid with the opposite charge is introduced into the human sequence or

B) one or several codons for a charged amino acid which are found in the FVIII cDNA of a hemophilic patient are replaced by a codon for an amino acid of the opposite charge.